Daxor Corporation, traded on the NYSE American under the symbol DXR, is a medical technology company specializing in advanced blood volume analysis. Headquartered in New York, Daxor develops, manufactures and markets diagnostic devices and reagents designed to provide clinicians with precise measurements of total blood volume, plasma volume and red cell mass. Its patented radioisotope dilution technology forms the cornerstone of its flagship BVA‐100 Blood Volume Analyzer, which is used in both clinical and research settings to support diagnosis and treatment planning.
The company’s product portfolio includes single‐use reagent kits, calibration and control materials, as well as service agreements for on‐site testing and technical support. Daxor’s blood volume analysis system is employed by hospitals, specialty clinics and pharmaceutical companies seeking to optimize patient care in areas such as heart failure management, critical care, hematology and nephrology. In addition to diagnostic applications, Daxor partners with academic medical centers and contract research organizations on clinical trials that require accurate blood volume measurements.
Founded in the late 1970s and publicly listed since the 1980s, Daxor has built a track record of regulatory clearances and scientific publications validating its technology. Over the years, the company has expanded its global reach, with installations and collaborations across North America, Europe and Asia. Its commitment to innovation is reflected in ongoing research efforts aimed at expanding the clinical indications for blood volume analysis.
Led by a management team with deep expertise in hematology, nuclear medicine and medical device commercialization, Daxor continues to invest in product development, quality assurance and customer training. With a focus on precision diagnostics and evidence‐based medicine, the company aims to help healthcare providers deliver more personalized and effective patient care worldwide.
AI Generated. May Contain Errors.
